Capitalizing on Mechanisms of Skin Cancer Development?  by Bard, Susan & Kirsner, Robert S.
journal club
1592 Journal of Investigative Dermatology (2011), Volume 131 © 2011 The Society for Investigative Dermatology
For the article: http://dx.doi.org/10.1038/jid.2011.48
QUESTIONS
1. What is nevoid basal cell carcinoma syndrome?
2. What studies were performed prior to a human trial with the topical medication?
3. How did the investigators study the medication in patients?
4. What were the results?
5. What did the investigators conclude?
Over the past decade, the hedgehog (HH) pathway has been found to be altered 
in patients with both syndromic and sporadic basal cell carcinoma (BCC) (Rohatgi 
and Scott, 2007). This pathway, when regulated, controls cell growth; however, 
alteration of the pathway results in cancer due to failure of patched 1, a compo-
nent of the HH pathway, to suppress the protein Smoothened (SMO), which leads 
to uncontrolled cell growth and BCC development. Thus, ways to manipulate this 
pathway have been conceptualized. A systemically administered (oral) specific 
SMO inhibitor has been used for locally advanced or metastatic BCCs and shown 
to produce an overall response rate of 55% (Von Hoff et al., 2009).
Despite these responses, obstacles to systemic treatment exist. For example, 
because activation of the HH pathway plays an important role in the hair growth 
cycle, hair growth inhibition (alopecia) resulted upon systemic treatment of BCC. 
Therefore, a more desirable delivery system may be topical application of an SMO 
antagonist. Because BCC is the most common cancer in the United States and 
is increasing in prevalence and cost, novel treatments for BCC are of substantial 
interest. Skvara and colleagues (2011, this issue) studied a topical SMO antago-
nist, LDE225, to determine (i) whether this agent affects BCC growth in vitro, (ii) 
whether topical delivery of this agent is feasible, and (iii) whether the topical SMO 
antagonist would be well tolerated in patients and have a positive effect on BCC.
These investigators found that topical application of an SMO antagonist is feasi-
ble and led to inhibition of basaloid nest formation in vitro and murine hair growth 
in vivo. Application of this SMO antagonist to BCCs in patients with nevoid BCC 
syndrome was found to affect HH pathway activation and clinically reduced the 
size of the cancers in almost all cases. Through the following questions, we examine this paper in greater detail. 
For brief answers, please refer to the supplementary information online <http://www.nature.com/jid/journal/v131/
n8/suppinfo/jid2011199s1.html>.
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